New York Life Investment Management LLC Takes Position in Revvity, Inc. (NYSE:RVTY)

New York Life Investment Management LLC purchased a new stake in shares of Revvity, Inc. (NYSE:RVTY - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 17,361 shares of the company's stock, valued at approximately $1,898,000.

Other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. acquired a new stake in shares of Revvity in the third quarter valued at about $1,579,487,000. Ceredex Value Advisors LLC purchased a new stake in Revvity during the 4th quarter worth approximately $108,353,000. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in shares of Revvity during the fourth quarter valued at approximately $33,568,000. Boston Trust Walden Corp acquired a new position in shares of Revvity during the fourth quarter valued at approximately $25,154,000. Finally, KBC Group NV purchased a new position in shares of Revvity in the third quarter valued at approximately $25,301,000. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Revvity Trading Up 0.3 %

RVTY traded up $0.35 on Tuesday, hitting $103.17. The company had a trading volume of 499,452 shares, compared to its average volume of 844,830. The company has a current ratio of 2.23, a quick ratio of 1.92 and a debt-to-equity ratio of 0.40. The firm has a market cap of $12.74 billion, a P/E ratio of 85.27, a PEG ratio of 2.62 and a beta of 1.09. The company's fifty day moving average price is $104.48 and its 200 day moving average price is $101.27. Revvity, Inc. has a 1 year low of $79.50 and a 1 year high of $131.96.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings results on Monday, April 29th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.94 by $0.04. The business had revenue of $649.90 million during the quarter, compared to analyst estimates of $646.83 million. Revvity had a return on equity of 7.37% and a net margin of 5.49%. The company's quarterly revenue was down 3.7% on a year-over-year basis. During the same period last year, the business posted $1.01 earnings per share. As a group, equities analysts expect that Revvity, Inc. will post 4.66 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 9th. Investors of record on Friday, July 19th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.27%. The ex-dividend date is Friday, July 19th. Revvity's payout ratio is currently 23.14%.

Analysts Set New Price Targets

RVTY has been the subject of several recent research reports. Raymond James increased their price objective on Revvity from $106.00 to $127.00 and gave the company an "outperform" rating in a research note on Friday, February 2nd. Robert W. Baird boosted their price target on shares of Revvity from $126.00 to $127.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 30th. UBS Group cut shares of Revvity from a "buy" rating to a "neutral" rating and upped their price objective for the company from $105.00 to $125.00 in a research note on Tuesday, January 16th. Barclays raised their target price on shares of Revvity from $92.00 to $105.00 and gave the stock an "equal weight" rating in a research note on Thursday, January 25th. Finally, TD Cowen upped their price target on Revvity from $123.00 to $130.00 and gave the company a "buy" rating in a research report on Tuesday, April 30th. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Revvity presently has a consensus rating of "Moderate Buy" and an average price target of $118.17.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.